Department of Radiology, Centre of Postgraduate Medical Education, Warsaw, Poland.
Department of Neurosurgery, Central Clinical Hospital of Ministry of the Interior and Administration, Warsaw, Poland.
J Neurointerv Surg. 2019 Aug;11(8):e3. doi: 10.1136/neurintsurg-2018-014469.rep. Epub 2019 May 23.
Patients suffering from malignant brain tumors are burdened with a grim prognosis. The blood brain barrier is considered a primary obstacle in therapeutic drug delivery to the brain. Intra-arterial (IA) delivery of therapeutic agents following osmotic BBB opening has been attempted for years, but high variability has limited its widespread implementation. It has been recently shown in animal studies that MRI is superior to X-ray for guiding IA infusions, as it allows direct visualization of the brain parenchyma perfused and facilitates predictable drug targeting. Moreover, PET imaging has revealed that IA, not intravenous, delivery of bevacizumab results in brain accumulation, providing strong rationale for utilizing the IA route. Here, we present our experience in a patient with recurrent butterfly glioblastoma enrolled in first-in-man MRI-guided neurointervention for targeted IA drug delivery.
患有恶性脑肿瘤的患者预后不佳。血脑屏障被认为是治疗药物向大脑输送的主要障碍。多年来,人们一直尝试通过渗透压性 BBB 开放进行颅内(IA)治疗药物输送,但高变异性限制了其广泛应用。最近的动物研究表明,MRI 优于 X 射线引导 IA 输注,因为它可以直接观察到灌注的脑实质,并有利于进行可预测的药物靶向。此外,PET 成像显示,贝伐单抗的 IA 给药而非静脉给药会导致大脑积聚,这为利用 IA 途径提供了强有力的理由。在这里,我们介绍了一位复发性蝶骨胶质母细胞瘤患者的经验,该患者参加了针对 IA 药物输送的首例 MRI 引导神经介入的人体试验。